Propel Bio Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 13, 2024), Propel Bio Management, LLC reported 28 stock positions worth $171.8 million. Its top holding was Applied Therapeutics (APLT) at 24.2% of the portfolio, followed by Simplify Enhanced Income ETF (HIGH, 16.3%) and Tscan Therapeutics (TCRX, 9.6%). Compared with Q4 2023, it opened 3 new positions, sold out of 9, added to 6 and reduced 1. The biggest buy was Simplify Enhanced Income ETF (HIGH, shares +1142%) and the biggest sale an exit from Plains GP (PAGP).
- Most Recent 13F
- Q2 2026
- Location
- Los Angeles, CA
- CIK
- 0001969764
- Portfolio Value
- $171.8M (Q1 2024)
- SEC Filing
- 0001829126-24-003275 ↗ filed May 13, 2024
Holdings Value
Holdings 28 stocks · $171.8M
| APLT Applied Therapeutics Inc. | 24.19% | 6,111,906 | $41.6M | Add +13.7% |
| HIGH Simplify Enhanced Income ETF | 16.29% | 1,492,581 | $28.0M | Add +1141.5% |
| TCRX Tscan Therapeutics Inc. | 9.65% | 2,087,139 | $16.6M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 6.69% | 43,032 | $11.5M | Add +43.3% |
| ACHV Achieve Life Sciences Inc. | 6.49% | 2,453,092 | $11.1M | New |
| PHAT Phathom Pharmaceuticals Inc. | 5.38% | 869,927 | $9.2M | Add +96.3% |
| AKRO Akero Therapeutics Inc. | 4.82% | 327,752 | $8.3M | Add +227.6% |
| FULC Fulcrum Therapeutics Inc. | 4.12% | 750,000 | $7.1M | No change |
| RNAM Avidity Biosciences Inc. | 2.65% | 178,500 | $4.6M | No change |
| DAWN Day One Biopharmaceuticals I | 2.60% | 270,664 | $4.5M | No change |
| ARDX Ardelyx Inc. | 2.52% | 594,174 | $4.3M | No change |
| ATHIRA PHARMA INC | 2.38% | 1,492,792 | $4.1M | No change |
| KURA Kura Oncology Inc. | 1.61% | 130,000 | $2.8M | No change |
| TSAT Telesat Corp. | 1.46% | 290,781 | $2.5M | No change |
| KYMR Kymera Therapeutics Inc. | 1.32% | 56,359 | $2.3M | No change |
| MBB iShares MBS ETF | 1.21% | 22,400 | $2.1M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 1.15% | 83,259 | $2.0M | New |
| MIRM Mirum Pharmaceuticals Inc. | 1.02% | 70,000 | $1.8M | No change |
| MRNS Marinus Pharmaceuticals Inc. | 0.95% | 180,100 | $1.6M | No change |
| KYN Kayne Anderson Energy Infra | 0.86% | 147,033 | $1.5M | No change |
| STRO Sutro Biopharma Inc. Com SHS | 0.64% | 195,000 | $1.1M | No change |
| TRVI Trevi Therapeutics Inc. | 0.52% | 260,000 | $897K | New |
| XFOR X4 Pharmaceuticals Inc. | 0.43% | 535,000 | $744K | No change |
| EIGRQ Eiger Biopharmaceuticals Inc. | 0.43% | 146,381 | $732K | Add +2.9% |
| LQD Ishr Ibx Usd Invgd CB ETF-Ui | 0.28% | 4,456 | $485K | No change |
| CYBIN INC | 0.20% | 850,000 | $351K | No change |
| FIDELITY INV MMTRSY 1 680 | 0.12% | 211,541 | $212K | Reduce -95.6% |
| CHINOOK THERAPEUTICS CVR | 0.02% | 79,357 | $31K | No change |
Portfolio Sells Q4 2023 → Q1 2024
| PAGP Plains GP Holdings LP | Sold out | 0.00% | −18.15 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −4.87 |
| FIDELITY INV MMTRSY 1 680 | Reduce -95.6% | 0.12% | −3.83 |
| BSV Vanguard Short-Term Bond ETF | Sold out | 0.00% | −1.77 |
| IBDP iShares Ibonds Dec 2024 Term | Sold out | 0.00% | −1.76 |
| SPSB SS SPDR P St C Corp. ETF | Sold out | 0.00% | −1.13 |
| SLQD iShares 0-5 YR Inv GRD Corp. | Sold out | 0.00% | −0.50 |
| FLRN SS SPDR BB Ig Float RT ETF | Sold out | 0.00% | −0.23 |
| HRTX Heron Therapeutics Inc. | Sold out | 0.00% | −0.15 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −0.11 |
Portfolio Buys Q4 2023 → Q1 2024
| HIGH Simplify Enhanced Income ETF | Add +1141.5% | 16.29% | +13.84 |
| APLT Applied Therapeutics Inc. | Add +13.7% | 24.19% | +9.26 |
| ACHV Achieve Life Sciences Inc. | New | 6.49% | +6.49 |
| AKRO Akero Therapeutics Inc. | Add +227.6% | 4.82% | +2.88 |
| PHAT Phathom Pharmaceuticals Inc. | Add +96.3% | 5.38% | +2.02 |
| SNDX Syndax Pharmaceuticals Inc. | New | 1.15% | +1.15 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +43.3% | 6.69% | +0.93 |
| TRVI Trevi Therapeutics Inc. | New | 0.52% | +0.52 |
| EIGRQ Eiger Biopharmaceuticals Inc. | Add +2.9% | 0.43% | −0.39 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 29 | $191.1M | PAGP, ACHV, CORT, PHAT, DCTH |
| Q1 2026 | 38 | $158.7M | PAGP, ACHV, PHAT, DCTH, CORT |
| Q4 2025 | 20 | $117.1M | PAGP, ACHV, PHAT, VRDN, MIST |
| Q3 2025 | 16 | $99.9M | PAGP, ACHV, AKRO, MIST, APLT |
| Q2 2025 | 16 | $82.4M | PAGP, ACHV, AKRO, PHAT, ABEO |
| Q1 2025 | 18 | $86.1M | PAGP, MDGL, AKRO, PHAT, ACHV |
| Q4 2024 | 21 | $100.7M | PAGP, MDGL, AKRO, ACHV, APLT |
| Q3 2024 | 21 | $172.4M | APLT, PAGP, PHAT, ACHV, TCRX |
| Q2 2024 | 24 | $154.2M | APLT, PAGP, TCRX, MDGL, ACHV |
| Q1 2024 | 28 | $171.8M | APLT, HIGH, TCRX, MDGL, ACHV |